title: Recent advances in the management of adult myositis.
abstract: Standard drug therapy of adult polymyositis, dermatomyositis and inclusion body myositis includes high-dose corticosteroids and cytotoxic drugs (methotrexate, azathioprine (AZA) and cyclophosphamide). Recent data are in favour of the early introduction of a cytotoxic or immunomodulating drug in addition to corticosteroid therapy. In patients with corticosteroid- and cytotoxic-resistant myositis, promising novel approaches to management include: iv. megadose pulse methylprednisolone combined with cytotoxic drugs, combination therapy with both methotrexate and AZA, cyclosporin, tacrolimus, fludarabine and iv. immunoglobulin (IVIG). Recent advances in the understanding of the role of cytokines and complement, in the pathogenesis of myositis, have led to preliminary therapeutic trials of three biological agents: etanercept, infliximab and anti-C5 monoclonal antibody.
authors.affiliation: Division of Rheumatology, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. adel.fam.@swchsc.on.ca
authors.forename: A G
authors.initials: AG
authors.lastname: Fam
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D006801:Humans; D009220:Myositis / Q000188:drug therapy* / Q000628:therapy; D026741:Physical Therapy Modalities
chemical_list: D015507:Drugs, Investigational